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Abstract
Background: Endothelial dysfunction in widely diffuse disorders, such as atherosclerosis, hypertension, diabetes and
senescence, is associated with nitric oxide (NO) deficiency. Here, the behavioural and molecular consequences deriving from
NO deficiency in human umbilical vein endothelial cells (HUVECs) were investigated.
Results: Endothelial nitric oxide synthase (eNOS) was chronically inhibited either by NG-Nitro-L-arginine methyl ester
(L-NAME) treatment or its expression was down-regulated by RNA interference. After long-term L-NAME treatment, HUVECs
displayed a higher migratory capability accompanied by an increased Vascular Endothelial Growth Factor (VEGF) and VEGF
receptor-2 (kinase insert domain receptor, KDR) expression. Moreover, both pharmacological and genetic inhibition of eNOS
induced a state of pseudohypoxia, revealed by the stabilization of hypoxia-inducible factor-1a (HIF-1a). Furthermore, NO
loss induced a significant decrease in mitochondrial mass and energy production accompanied by a lower O2 consumption.
Notably, very low doses of chronically administered DETA/NO reverted the HIF-1a accumulation, the increased VEGF
expression and the stimulated migratory behaviour detected in NO deficient cells.
Conclusion: Based on our results, we propose that basal release of NO may act as a negative controller of HIF-1a levels with
important consequences for endothelial cell physiology. Moreover, we suggest that our experimental model where eNOS
activity was impaired by pharmacological and genetic inhibition may represent a good in vitro system to study endothelial
dysfunction.
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Introduction
Integrity of endothelial cells is crucial for the maintenance of
vascular homeostasis. The endothelium explicates its physiological
functions by producing active molecules, among which nitric oxide
(NO) is particularly important. By diffusing into neighboring
smooth muscle cells, endothelial-produced NO induces vasorelax-
ation, thereby controlling blood pressure levels [1,2]. NO generated
in the endothelium also has antiaggregant activity that protects the
cardiovascular system from thrombosis and acute events [2].
Consistent with the key role of this gaseous messenger in
cardiovascular physiology, NO loss is a dangerous event that is
associated with endothelial dysfunction typical of diffuse patho-
logical conditions like atherosclerosis and senescence [3–5].
Moreover, the deficiency of NO and endothelial nitric oxide
synthase (eNOS) activity is thought to be crucial for the
development and/or acceleration of the important vascular
complications associated with diabetes [6].
In addition to its effect on smooth muscle cells and platelets, NO
generated by the endothelium has important functions in the
endothelial cells (ECs) themselves. Indeed, the gaseous messenger
plays a key role in the process of angiogenesis, stimulating
proliferation, migration and differentiation of ECs to form new
blood vessels [7]. In particular, NO acutely produced by
angiogenic factors, such as Vascular Endothelial Growth Factor
(VEGF) [8–10], endothelin [11], substance P [12] and oxytocin
[13] is crucial for stimulation of EC migration.
Together with the stimulatory effect of acute NO on EC
chemotaxis, also the concentration and timing of NO release
appear to be of crucial importance in determining the final
outcome on EC physiology. In particular, recent work from our
laboratory has demonstrated that long term inhibition of eNOS in
Human Umbilical Vein ECs (HUVECs) by exposure to the NOS
inhibitor NG-Nitro-L-arginine methyl ester (L-NAME), increases
the migratory behaviour of these cells in Boyden chambers assays
carried out immediately after removal of the drug [14]. These
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results suggest that basal NO, at variance with the gas released
acutely in response to motogenic factors, diminishes the migratory
ability of ECs. The tonic inhibitory effect of basal NO on
migration, by acting as a brake on inappropriate migration, could
prevent exaggerated angiogenic responses and thus be an
important homeostatic factor in EC physiology.
In the present study, we have further investigated the effects of
chronic NO deprivation on EC physiology, and attempted to
unravel the pathway linking basal NO to migratory ability. Results
obtained both by long term pharmacological inhibition and by
genetic silencing of eNOS indicate that NO loss induces profound
modifications in EC physiology, leading to a general decrease of
mitochondrial mass and metabolic activity, to an accumulation of
Hypoxia Inducible Factor-1a (HIF-1a) in normoxia and to
enhanced chemotactic migration as a consequence of the
increased HIF-1a levels. These results have important implication
for our understanding of the consequences of NO deprivation in
cardiovascular pathology.
Results
HUVECs chronically treated with L-NAME are not
apoptotic, but have decreased mitochondrial mass and
function
To characterize the effects of long term NO deprivation on
human ECs, we first analyzed possible changes in cell viability. As
shown in Figure 1A, treatment with L-NAME for 48 h did not
induce caspase-3 cleavage, which instead occurred when HU-
VECs were exposed to high glucose (30 mM for 48 h), a condition
known to be apoptotic for these cells [15]. Moreover, quantifica-
tion of apoptosis/necrosis by annexin V-conjugated FITC and PI
staining followed by FACS analysis did not show any difference in
the apoptotic index between control and L-NAME treated
HUVECs (0.1660.03 and 0.1560.05 in control and L-NAME
treated cells, respectively). Also the percentage of necrotic cells was
unaffected by the treatment, ranging from 8.360.26% in control
cells to 4.160.21% in cells treated with L-NAME. Finally, we
checked the levels of Bcl-2 and Bax, well-known proteins involved
in the regulation of apoptosis endowed with anti-apoptotic and
pro-apoptotic activity respectively, and found that their expression
was unchanged by L-NAME treatment (Figure 1B).
In HeLa cells and adipocytes, basal NO enhances mitochon-
drial mass [16,17], however the effect of the gas on mitochondrial
biogenesis in ECs had not been investigated. As shown in
Figure 1C, HUVECs treated with L-NAME for 48 h showed a
decreased amount of mitochondrial DNA (mtDNA) as compared
to untreated cells (by 3860.05%). Moreover, incorporation of the
metabolic indicator MTS was lower in L-NAME treated cells (with
a mean reduction of 2665%) (Figure 1D) indicating a decreased
mitochondrial activity in NO deficient cells as compared to control
cells. In agreement, oxygen consumption as well as ATP levels
were reduced in the L-NAME treated cells (Figures 1E and F).
The NO donor DETA-NO completely reverts the increased
migratory behavior induced in HUVECs by long-term L-
NAME treatment
Our previous results demonstrated that long-term treatment of
HUVECs with L-NAME induced a strong increase of the cell
migratory capacity assayed in Boyden chambers [14]. These
results suggested that chronic, constitutive NO production exerts a
tonic inhibition on HUVEC migratory behavior. To validate this
hypothesis, we investigated whether long-term administration of
the slow NO donor DETA-NO would reverse the L-NAME-
enhanced migration of HUVECs. As shown in Figure 2A,
chronic treatment of HUVECs with L-NAME for 48 h was
confirmed to increase the cell migratory response to VEGF by
about 45%. Notably, also basal migration was augmented in a
similar manner. No significant increase in cell migratory behavior
was observed after 24 h treatment with L-NAME (data not
shown). A dose as low as 500 nM of DETA-NO, supplied to the L-
NAME treated cells for the last 24 h of the treatment, completely
abolished the increased migration observed in both basal and
VEGF-stimulated NO deficient HUVECs, thus confirming that
enhanced HUVEC migration caused by L-NAME was due to NO
deprivation. Notably, cells treated with the combination of L-
NAME and DETA-NO showed diminished migration compared
to cells treated with the donor alone. This result can probably be
explained by a biphasic effect of chronic NO, as demonstrated for
HeLa cells in our previous work [14].
To investigate whether the increased migratory behavior caused
by chronic NOS inhibition was due to a deficiency in cyclic GMP
(cGMP) consequent to NO deprivation, we evaluated the effect of
long-term treatment with the guanylate cyclase inhibitor ODQ on
HUVEC migration in Boyden chambers. After treatment of the
cells for 48 h either with L-NAME or with ODQ, migration assays
were performed in the absence of the drugs. As shown in
Figure 2B, chronic treatment with ODQ did not induce any
change either in basal or in VEGF-stimulated HUVEC motility.
The measurement of cGMP accumulation in HUVECs chroni-
cally treated with L-NAME or ODQ confirmed the ability of both
drugs to significantly reduce cGMP levels (Figure 2C). These
results indicated that blunting of the cGMP signaling pathway is
not involved in the stimulatory effect induced by NO depletion.
Effects of long term L-NAME treatment on eNOS, VEGF,
KDR expression and VEGF signaling in HUVECs
We previously considered the hypothesis that the improved
migratory ability of HUVECs chronically treated with L-NAME
could be caused by a rebound effect: expression of eNOS in
response to its chronic inhibition could have been increased, thus
stimulating migration via enhanced NO release upon exposure of
the cells to motogenic factors in the absence of the inhibitor. Our
analysis, however, suggested that eNOS was not increased by
chronic L-NAME treatment [14]. To investigate this phenomenon
further, we quantitatively analyzed both eNOS protein and
mRNA levels in treated and untreated cells. As shown in
Figure 3A, a significant decrease in eNOS protein levels (by
4865%) was detected in treated cells. In contrast, no variation in
the eNOS mRNA level, measured by RT-qPCR, was observed
(1.0460.3 fold in comparison to untreated cells) (Figure 3B),
suggesting that chronic inhibition of eNOS causes an increased
degradation of the enzyme and/or impairment of the translation
of its mRNA.
In an attempt to explain the mechanism through which NO
deprivation enhances migration, we investigated how chronic L-
NAME treatment affects the expression levels of the VEGF
receptor-2 (kinase insert domain receptor, KDR). We also
analyzed VEGF itself, as endogenous production of the growth
factor could potentiate migration by an autocrine loop. RT-qPCR
analysis demonstrated that both VEGF and KDR mRNA levels
increased, 1.9160.2 and 1.7960.2 fold respectively, in treated
compared to untreated cells (Figure 3C). In addition, increased
VEGF production and KDR protein expression was demonstrated
by ELISA measurement and biochemical analysis of HUVEC
lysates, respectively. As shown in Figure 3D, quantitative
measurements of the secreted protein revealed a 1.7-fold increase
of VEGF in conditioned media from L-NAME treated cells in
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comparison to untreated cells. Similarly, KDR protein level in
cells chronically treated with L-NAME is 1.8-fold increased as
compared to untreated cells (Figure 3E), in good agreement with
the RT-qPCR data.
A major VEGF signaling pathway involved in endothelial cell
migration includes the activation of phosphatidylinositol-3-kinase
(PI-3-K) and the subsequent phosphorylation of the protein kinase
AKT, which in turn activates eNOS by phosphorylating it on
Ser1177. To determine if L-NAME treatment modified the ability
of VEGF to activate this pathway, the phosphorylation state of
eNOS and AKT after a 5-min VEGF stimulation in control and
chronically L-NAME treated cells was measured. As shown in
Figure 3F, in control cells VEGF (25 ng/ml) increased eNOS
and AKT phosphorylation by about 3 times, as expected (lane 2).
In L-NAME treated cells, the basal levels of eNOS and AKT
phosphorylation were already increased (see lane 3 vs lane 1), and
VEGF was not able to induce any further phosphorylation (lane 4).
A densitometric analysis performed on 4 independent experiments
revealed that in L-NAME treated cells the basal level of
phosphorylated eNOS was 3.4360.94 times greater than in
control cells. The increase was less pronounced when the basal
level of phosphorylated AKT was compared in treated and control
cells (1.5760.24 times).
The results presented in Figs. 3 C-F are consistent with an
activated VEGF/KDR system in L-NAME-treated HUVECs,
and could explain the enhancement of both basal and VEGF-
stimulated chemotactic response in these cells.
Inhibition of basal NO production induces nuclear HIF-1a
accumulation in HUVECs
Increased VEGF production and cell motility are typical events
occurring in hypoxic cancer cells, due to the accumulation of
Figure 1. Effect of chronic NO deprivation on HUVEC vitality and mitochondrial mass and function. (A) Lysates of HUVECs treated for
48 h with 5 mM L-NAME or 30 mM glucose (high glucose, h-Glc) were separated by 12% SDS-PAGE and immunoblotted with an anti-caspase 3
antibody which recognized full length caspase-3 (35 kDa) and its large fragment resulting from cleavage (17 kDa). b-actin was used as a loading
control. Shown is a representative blot of 2 comparable experiments. (B) Total cell lysates prepared as described in (A) were separated by SDS-PAGE
and immunoblotted with anti Bcl–2 or anti Bax antibodies. b-actin was used as a loading control. Shown is a representative blot of 2 comparable
experiments. (C) Mitochondrial DNA (mtDNA) was quantified by RT-qPCR from control cells (CTRL) or from cells treated with L-NAME for 48 h, and
normalized to the level of the housekeeping gene 18S. **p,0.01; t test; n = 3. (D) Mitochondrial activity of control and L-NAME treated cells was
evaluated by means of MTS. In parallel samples, the total cell number was measured by crystal violet staining. ***p,0.001 vs control cells (CTRL, set at
100%); t test; n = 7. (E) After L-NAME treatment, oxygen consumption was reduced by 2566% in comparison to control cells. The values were
normalized to the cell protein content. *p,0.05; t test, n = 3. (F) Total cellular ATP levels were reduced by 2567% after 48 h of 5 = mM L-NAME
treatment. **p,0.01 vs control cells (CTRL, set at 100%); t test; n = 8.
doi:10.1371/journal.pone.0029680.g001
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hypoxia-inducible factor-1a (HIF-1a), which plays a major role in
the transcriptional activation of genes encoding angiogenic factors
[18,19]. Similarly, induction of VEGF expression during hypoxia
has been described also in endothelial cells [20]. We therefore
analysed the effect of long term L-NAME treatment on HIF-1a
levels in HUVECs. Most interestingly, we observed that, after 48 h
of treatment, L-NAME induced nuclear accumulation of HIF-1a
in HUVECs (5.561.6 fold over basal) (Figures 4A and B). RT-
qPCR analysis revealed no significant change in HIF-1a mRNA
levels after L-NAME treatment (1.2160.1 fold in comparison to
untreated cells) (Figure 4C), suggesting that HIF-1a accumula-
tion in L-NAME-treated cells was mainly due to its stabilization, as
occurs under hypoxic conditions. Taken together, these data
suggest that prolonged L-NAME treatment induces in endothelial
cells a pseudohypoxic state, with the consequent stabilization of
HIF-1a under normoxic conditions.
In addition to HIF-1a, other factors could contribute to the up-
regulation of VEGF expression [21]. To directly correlate the
increase in VEGF expression induced in HUVECs by L-NAME
treatment to the transcriptional activity of HIF-1, we performed
experiments in which L-NAME treated cells and control cells were
transfected with a plasmid expressing a dominant negative form of
the HIF-1b subunit (DARNT), which maintains the capacity of
forming an heterodimer but cannot bind DNA [22,23]. As shown
in Figure 4D, in HUVECs, the increase in VEGF protein
induced by L-NAME treatment was totally blunted, confirming
the central role of HIF-1a as regulator of VEGF expression in
NO-deprived endothelial cells. Moreover, as shown in Figure 4E,
transfection with DARNT inhibited also the increased migratory
capacity induced in HUVECs by L-NAME treatment.
The NO donor DETA-NO reverts the effects of L-NAME
treatment on HIF-1a stabilization, and on VEGF and
eNOS expression
To investigate whether the observed effects of L-NAME
treatment on HUVEC gene expression were due to the chronic
depletion of NO, we reconstituted NO levels by utilizing the long
lasting NO donor DETA-NO. The addition of 500 nM DETA-
NO completely reverted the stabilization of nuclear HIF-1a, the
reduced expression of total eNOS protein (Figure 5A) and the
increase in VEGF mRNA levels (Figure 5B), which are all
characteristic features detected in the long-term L-NAME treated
cells.
Silencing of eNOS mimics the effects of long-term L-
NAME treatment of HUVECs
To further investigate if the observed effects of L-NAME
treatment were due to the specific inhibitory effect on eNOS
activity, expression of the enzyme was silenced in HUVECs by
Figure 2. The enhancement in HUVEC migration induced by L-NAME is reverted by the NO donor DETA-NO and is independent of
the cGMP pathway. (A) HUVECs were treated for 48 h with 5 mM L-NAME in the absence or in the presence of 500 nM DETA/NO for the last 24 h,
as indicated. Chemotaxis experiments were then performed using 25 ng/ml VEGF as attractants. Results are expressed as the number of migrating
cells. #p,0.001 vs basal migration in control cells (CTRL); 1p,0.01 vs VEGF-induced migration in control cells; ***p,0.001 vs basal migration in L-
NAME treated cells; uuup,0.001 vs VEGF-induced migration in L-NAME treated cells; no significant differences between control and DETA/NO treated
cells (One-way ANOVA with Bonferroni’s test, n = 15). (B) HUVECs were treated for 48 h with 5 mM L-NAME or 1 mM ODQ, and chemotaxis
experiments were performed as described in (A). Results are expressed as the number of migrating cells in the different experimental conditions.
#p,0.001 vs basal migration in control cells (CTRL); 1p,0.001 vs VEGF-induced migration in control cells; no significant differences between control
and ODQ treated cells (One-way ANOVA with Bonferroni’s test, n = 3). (C) cGMP accumulation in HUVECs treated for 48 h with L-NAME or ODQ was
evaluated by EIA and expressed as pmol of cGMP normalized to the cell protein content (pmol/mg protein). ***p,0.001; One-way ANOVA with
Bonferroni’s test; n = 3.
doi:10.1371/journal.pone.0029680.g002
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using RNA interference methodology. HUVEC transfection with
eNOS siRNA caused a mean reduction in eNOS protein levels of
7060.1% (Figure 6A). In agreement with the results obtained
after long-term exposure to L-NAME, HIF-1a accumulated in the
nucleus of eNOS knock-down cells, whereas cells transfected with
control siRNA were unaffected (Figure 6B). Moreover, in eNOS
silenced HUVECs, again similarly to long term L-NAME treated
cells, VEGF production was increased (Figure 6C), while the
amount of mtDNA as well as ATP levels were decreased
(Figure 6D).
Discussion
Our results demonstrate that long-term pharmacologic and
genetic down-regulation of eNOS induce relevant effects in
HUVECs. The long-term treatment with L-NAME induced a
significant decrease in mtDNA amount, accompanied by de-
creased mitochondrial activity and ATP production. This
observation is in agreement with previous results, which showed
the important role of the gas in promoting mitochondrial
biogenesis in different cell types and tissues [16,17]. Similar results
(i.e. decreased mitochondrial mass) were obtained in the
microvasculature of mice treated with NG-monomethyl-L-arginine
(L-NMMA) for a long period of time (1–2 months) [24]; however,
given the length of the treatment, these results are not directly
comparable to ours. To our knowledge, the effect of NO
deprivation for shorter times (days) on mitochondrial biogenesis
in ECs had not previously investigated. Our work demonstrated
that HUVECs respond to NO deprivation already after 48 h of
treatment, making them a useful model for the investigation of the
effects of the gas on mitochondrial biogenesis and function.
An important consequence of the decrease in NO production
observed by us is the accumulation of HIF-1a in the nucleus, with
a resulting adaptation of gene expression to a pseudohypoxic state,
Figure 3. Effects of L-NAME treatment on eNOS, VEGF and KDR expression. (A) Densitometric analysis of eNOS protein expression.
***p,0.001; t test; n = 11. Inset: a representative blot out of eleven is shown. Total eNOS protein was evaluated by western blotting on lysates
prepared from control cells (lane 1) or from 48 h L-NAME treated cells (lane 2). b-actin was used as a loading control. (B) eNOS RNA levels were
measured by RT-qPCR and normalized to the level of the housekeeping gene 18S. No significant differences between control and L-NAME treated
cells (t test, n = 3). (C) VEGF and KDR RNA levels were measured by RT-qPCR and normalized to the level of the housekeeping gene 18S. **p,0.01 vs
control cells (CTRL); t test; n = 624 for VEGF and KDR, respectively. (D) VEGF protein levels were detected by ELISA measurement in conditioned
media collected from control or 48 h L-NAME treated cells. Results are expressed as pg of VEGF normalized to the cell protein content (pg/mg
protein). **p,0.01; t test; n = 3. (E) KDR protein was visualized by western blot after immunoprecipitation with KDR antibodies of HUVEC lysates
obtained from control (lane 1) or from 48 h L-NAME treated cells (lane 2). An aliquot of total cell lysates was immunoblotted with b-actin antibodies
as a control (input). Shown is a representative blot of 2 comparable experiments. (F) Control cells (lanes 1 and 2) or 48 h L-NAME treated cells (lanes 3
and 4) were stimulated for 5 min with 25 ng/ml VEGF. Aliquots of cell lysates were separated by 10% SDS-PAGE and immunoblotted with the
indicated antibodies. Actin was used as a loading control. Shown is a representative blot of 4 comparable experiments.
doi:10.1371/journal.pone.0029680.g003
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i.e. a state of hypoxia in the presence of normal levels of oxygen.
The increased expression of VEGF found in our experiments can
be considered a consequence of this pseudohypoxic state since the
dominant negative form of the HIF1-b subunit DARNT totally
blunted the VEGF protein increase induced by L-NAME
treatment. Accordingly, DARNT transfection inhibited also the
increased motility in L-NAME treated HUVECs, thus indicating
that the migratory behavior we observed in the treated cells can be
considered the consequence of the transcriptional activity of HIF-
1a. Of note, the increased HUVEC motility is observed despite a
reduction in eNOS levels, and is not induced by chronic treatment
with the guanylate cyclase inhibitor ODQ, indicating that cGMP
and protein kinase G (PKG) are not involved in the observed
effects.
Our results open the interesting question of the mechanism by
which NO deficiency induces HIF1astabilization in HUVECs.
HIF-1a degradation depends on prolyl hydroxylases-catalysed
proline hydroxylation, which induces binding of the factor to an
ubiquitin ligase (the Von-Hippel Lindau protein) and targets it for
proteasomal degradation. The activity of prolyl hydroxylases
(PHDs) is dependent on the availability of oxygen and 2-
oxoglutarate (a Krebs cycle intermediate) as substrates and on
Fe2+ and ascorbate as cofactors. In addition to these mechanisms
controlling HIF levels, HIF-1a transcriptional activity can also be
negatively controlled via hydroxylation of an asparaginyl residue
operated by an O2 dependent enzyme called Factor Inhibiting
HIF (FIH-1) [25]. Under hypoxic conditions, PHD and FIH-1
activity are inhibited and HIF-1a accumulates in the nucleus to
function as a transcription factor and to evoke adaptive responses
to changes in tissue oxygenation. Under our experimental
conditions, chronic eNOS inhibition induces HIF-1a nuclear
accumulation, apparently as a result of a decreased degradation,
Figure 4. L-NAME treatment induces HIF-1a nuclear accumulation. (A) HIF-1a protein levels were detected by western blotting of nuclear
extracts from control HUVECs (lane 1) or from HUVECs treated with L-NAME for 48 h (lane 2). Shown is a representative blot of 4 comparable
experiments. HIF-1a migrates as a doublet with apparent molecular weight of 118 and 120 kDa. (B) Densitometric analysis of nuclear HIF-1a protein
levels. *p,0.05; t test; n = 4. (C) HIF-1a RNA levels were measured by RT-qPCR and normalized to the level of the housekeeping gene 18S. No
significant differences between control and L-NAME treated cells (t test; n = 3). (D) VEGF protein levels were detected by ELISA measurement in
conditioned media collected from HUVECs transfected with the empty vector (pcDNA3) or with the expression vector DARNT, and treated with L-
NAME for the 48 h following transfection. Results are expressed as pg of VEGF normalized to the cell protein content (pg/mg protein). **p,0.01 vs
untreated cells transfected with pcDNA3; ***p,0.001 vs L-NAME treated cells transfected with pcDNA3 (One-way ANOVA with Bonferroni’s test;
n = 3). (E) HUVECs were transfected with pcDNA3 or DARNT, and treated with L-NAME for the 48 h following transfection when indicated. Chemotaxis
experiments were then performed using 25 ng/ml VEGF as attractant. Results are expressed as the number of migrating cells. #p,0.001 vs basal
migration in untreated pcDNA3 cells; 1p,0.001 vs VEGF-induced migration in untreated pcDNA3 cells; ***p,0.001 vs basal migration in pcDNA3 cells
treated with L-NAME; uuup,0.001 vs VEGF-induced migration in pcDNA3 cells treated with L-NAME; no significant differences between untreated
pcDNA3 and DARNT transfected cells and between untreated and L-NAME treated DARNT tranfected cells (One-way ANOVA with Bonferroni’s test,
n = 10).
doi:10.1371/journal.pone.0029680.g004
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supporting the hypothesis of an impaired PHD activity. The
question is then shifted to the mechanism through which NO may
affect PHD activity in HUVECs.
It is well known that NO competes with O2 for the binding to
the heme moiety of cytochrome C oxidase [26–28]. Therefore, a
possibility that we considered was that NO deficiency, by
activating mitochondrial respiration, could cause an intracellular
O2 redistribution from the cytoplasm to the mitochondria [29],
thus inducing oxygen depletion and PHD inactivation in the
cytosol. However, it is unlikely that cytoplasmic hypoxia could
have occurred in our experimental conditions where cells are
exposed to an atmospheric O2 concentration (21% O2) [30]. In
addition, in NO deficient cells we observed a lower oxygen
consumption, which can be explained by the reduced mitochon-
drial mass, thus making the hypothesis of an O2 redistribution
from the cytoplasm to the mitochondria difficult to support. We
conclude therefore that NO deficiency affects PHD activity under
normoxic conditions.
The relationship between NO and HIF-1a is complex and
matter of intense debate [31]. Recent studies have suggested a dual
role for NO in regulating HIF-1a function. By using NO donors or
the controlled expression of an inducible NOS, it has been found
that high concentrations of NO induced HIF-1a nuclear
accumulation, even under normoxic conditions, whereas under
hypoxic conditions, when HIF-1a levels are already high, low
physiological concentrations of NO appear to have the opposite
effect [32–37]. The effects of the gas under the latter conditions
are similar to those observed here. Further underscoring the
similarity, the involvement of soluble guanylate cyclase and cGMP
in the low NO-induced reduction of HIF-1a was, like in our
migration experiments, excluded [32–34,38]. However, differently
from the previously reported results, in our experiments, the ECs
were not subjected to hypoxic conditions. It is possible that in ECs,
the O2 threshold for HIF-1a stabilization is higher than in other
cells, and that under normoxic conditions, basal NO production
counteracts the stabilization that would otherwise occur.
It should be also considered that PHD activity is affected not
only by O2, but also by the availability of iron, ascorbate and the
Krebs cycle intermediate 2-oxoglutarate [39]. The deficiency of
NO may influence the intracellular availability of one or more of
these factors, thus decreasing the enzymatic activity and causing
HIF-1a accumulation. We cannot however exclude that other
stabilizing mechanisms, not directly linked to PHD, are involved
[40]. Furthermore, the possibility that reactive oxygen species may
play a role is now under investigation in our laboratory. Certainly,
more work is needed to clarify these important points.
In our experiments very low concentrations of DETA-NO
abrogated the HIF-1a accumulation, the VEGF increased
expression and the increased motility found in L-NAME treated
cells. On the basis of this result one can hypothesize that low levels
of the gas constantly produced by ECs under basal conditions
contribute to keep HIF-1a levels under control. In other words,
under physiological conditions, the ECs, by producing constitutive
NO, could control all of the events set in motion by HIF-1a,
including cell motility and VEGF production. In case of NO
deficiency, HIF-1a would be released from this brake, would
escape degradation and consequently accumulate, as shown in our
experiments.
In conclusion, our results show that lack of NO in human
endothelial cells induces pseudohypoxia and mitochondrial
dysfunction with consequent decreased energy production. These
events may very well occur in all of those pathological conditions
where eNOS expression and/or activity are impaired, as in
hypertension, type 2 diabetes, hypercholesterolemia, thus contrib-
uting to the endothelial dysfunction typical of such disorders. Our
experimental model where eNOS activity was impaired by
pharmacological and genetic inhibition may represent a good in
vitro system to study the effect of NO deficiency on vascular
endothelial cells, and to find new therapeutic target (HIF-1a




Human umbilical vein endothelial cells (HUVECs) were
isolated from freshly derived umbilical cords by digestion with
collagenase as described by Jaffe et al. [41]. Umbilical cords were
donated anonymously after informed consent according to
national ethical legislation. Cells were routinely grown in 199
medium, supplemented with 20% heat-inactivated fetal bovine
serum (FBS), 100 mg/ml endothelial cell growth supplement
(ECGS) and 50 mg/ml heparin, and used at passages 2–7. Where
indicated, HUVECs were treated with 5 mM NG-Nitro-L-arginine
Figure 5. The NO donor DETA-NO reverts the effects of L-
NAME treatment on HIF-1a stabilization, and on VEGF and
eNOS expression. (A) HIF-1a protein levels were detected by western
blotting of nuclear extracts from HUVECs treated with L-NAME and/or
DETA/NO as described in Fig. 2A. An aliquot of total cell lysates was
immunoblotted with anti eNOS antibodies, and with anti b-actin
antibodies as loading control. A representative blot of 3 comparable
experiments is shown. (B) VEGF RNA levels were measured by RT-qPCR
and normalized to the level of the housekeeping gene 18S. *p,0.05 vs
control cells (CTRL); **p,0.01 vs L-NAME treated cells; no significant
differences between control and DETA/NO treated cells (One-way
ANOVA with Bonferroni’s test; n = 3).
doi:10.1371/journal.pone.0029680.g005
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methyl ester (L-NAME) in 199 medium containing 10% FBS for
48 h preceding the experiments. The concentration of L-NAME
was chosen according to Papapetropoulos et al. [10].
Apoptosis assays
Quantification of apoptosis/necrosis was performed by Annexin
V-FITC conjugate and propidium iodide (PI) staining (Abcam,
Cambridge, UK) followed by fluorescence activated cell sorting
(FACS) performed with a FACScalibur flow cytometer equipped
with a 488 nm argon laser (Becton Dickinson, San Jose´, CA,
USA). The collected data were evaluated by Cell Quest software.
The degree of apoptosis was calculated as apoptotic index
considering cells both in early and late apoptosis. In addition,
active caspase-3, Bcl-2 and Bax proteins were detected by western
blot on total cell lysates.
Evaluation of mitochondrial DNA (mtDNA)
Total DNA was extracted with QIAamp DNA extraction kit
(Qiagen, Hilden, Germany), and mtDNA levels were amplified
with primers specific for the mitochondrial cytochrome b (CytB)
gene and normalized to genomic DNA by amplification of the
rRNA 18S nuclear gene. Primers used were: for CytB, F, 59–
CTTCGCTTTCCACTTCATCTTACC-39 and R, 59-TTGGGTTGTTTGATCCT-
GTTTCG-39, and for 18S, F, 59-CTGCCCTATCAACTTTCGATGGTAG-39
and R, 59-CCGTTTCTCAGGCTCCCTCTC-39. Quantitative real time
PCR (RT-qPCR) reactions were run with the iQ SybrGreenI
SuperMix (Bio-Rad, Segrate, Italy) on an iCycler iQ Real-Time
PCR detection system (Bio-Rad) using 50 ng of total DNA.
Calculations were performed with the 22DDCt methods using 18S
rRNA as an internal control.
Oxygen consumption
Cellular oxygen consumption was measured as previously
described [42]. Briefly, HUVECs were re-suspended in respiration
buffer (0.3 M mannitol, 10 mM KCl, 5 mM MgCl2, 10 mM
K2PO4, pH 7.4) [43] at a density of 3.0610
6/ml, and analyzed at
37uC in a gas-tight vessel equipped with a Clark-type oxygen
electrode (Rank Brothers Ltd., Cambridge, UK) connected to a
chart recorder. Protein content in cell samples was determined by
the bicinchoninic acid (BCA) protein assay (Thermo Scientific,
Rockford, IL, USA).
Cell metabolism assays
Cell metabolism was assessed by means of a Cell Titer 96H
Aqueous ONE Solution Reagent colorimetric assay (MTS,
Promega, Madison, WI, USA), and the total cellular ATP content
using a CellTiter-GloH Luminescent Assay (Promega). Both the
assays were performed according to the manufacturer’s instruc-
tions on HUVECs plated at a density of 26104 cells/well in 96-
well microplates. Optical density at 490 nm (for MTS) and
luminescence (for ATP) were measured using a multiplate
spectrophotometer (VictorTM, PerkinElmer, Waltham, MA,
USA). On parallel wells, cell proliferation was evaluated by crystal
violet staining. Briefly, cells were fixed with 100% methanol, and
Figure 6. Effect of eNOS silencing on HIF-1a accumulation, VEGF secretion, mtDNA and ATP levels. (A) Characterization of HUVECs
transfected with eNOS siRNA: densitometric analysis of eNOS protein expression where eNOS protein levels were normalized to b-actin protein.
***p,0.001; t test; n = 4. Inset: representative blots of eNOS protein in cells transfected with control (ctrl) or eNOS siRNA. (B) HUVECs were transfected
with control (lane 2) or eNOS siRNA (lane 3), and HIF-1a protein was detected by western blotting on the corresponding nuclear extracts. In lane 1,
nuclear extracts from untransfected cells. An aliquot of total cell lysates was immunoblotted with anti eNOS antibodies to check silencing, and with
anti b-actin antibodies as loading control. A representative blot of 2 comparable experiments is shown. (C) VEGF protein levels were detected by
ELISA measurement in conditioned media collected from HUVECs 48 h after transfection with control or eNOS siRNA. Results are expressed as pg of
VEGF normalized to the cell protein content (pg/mg protein). *p,0.05; t test; n = 3. (D) MtDNA (left axis) and total cellular ATP content (right axis)
were measured in HUVECs transfected for 48 h with control or eNOS siRNA. In silenced cells, mtDNA and ATP were reduced by 3660.4 and 4569.7%
respectively. **p,0.01 and ***p,0.001; t test; n = 3.
doi:10.1371/journal.pone.0029680.g006
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then stained with a 0.1% crystal violet solution. After extensive
washes with deionized water, the dye was solubilized in 10% acetic
acid solution, and the absorbance was measured at 595 nm.
Cell migration assays
HUVEC migration was evaluated by means of chemotaxis
experiments in a 48-well modified Boyden chamber, as previously
described [13,14]. Briefly, the filters coated with 10 mg/ml of type
IV collagen were placed over a bottom chamber containing
25 ng/ml VEGF as attractant factor. The cells, suspended in 199
media containing 2% FBS, were added to the upper chamber at a
density of 5.06104 cells/well. After 6 h of incubation at 37uC, the
cells that had migrated to the lower side of the filter were stained
with Diff-Quick stain (VWR Scientific Products, Bridgeport, NJ,
USA), and 5 unit fields per filter were counted by a scorer blind to
the experimental conditions using a Zeiss microscope. The assays
were run in triplicate.
Determination of cGMP accumulation
HUVECs were cultured in 60-mm Petri dishes and treated for
48 h with L-NAME or ODQ. During the last 30 min of
treatment, 1 mM isobutylmethylxanthine (IBMX) was added to
inhibit phosphodiesterases. cGMP was extracted in 500 ml of
0.1 N HCl, and its quantification was performed by an enzyme
immunoassay (EIA) kit (Enzo Life Sciences, Vinci-Biochem, Vinci,
Firenze, Italy) following manufacturer’s instructions for the
acetylated assay procedure.
Immunoblot and immunoprecipitation analyses
For immunoblot analysis, HUVECs, plated in 35-mm
diameter Petri dishes, were washed with phosphate-buffered
saline (PBS), and then directly lysed in SDS-PAGE sample buffer
(62 mM Tris-HCl pH 6.8, 2% sodium dodecyl sulfate (SDS),
10% glycerol, 5% 2-mercaptoethanol, and 0.04% bromophenol
blue). After SDS-PAGE electrophoresis, proteins were transferred
onto nitrocellulose membranes that were blocked with 5% (w/v)
non fat dried milk in Tris-buffered saline containing 0.05%
Tween-20 (TBS-T), and probed overnight with the indicated
primary antibodies. After incubation with the appropriate
peroxidase-conjugated secondary antibody (DAKO, Denmark),
the immunoreactive bands were visualized by chemiolumines-
cence (LiteAblot Plus, EuroClone, Italy). For KDR immunopre-
cipitation, HUVECs were washed with PBS and lysed for 10 min
on ice with RIPA buffer (20 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS, 1 mM b-glycerophosphate, 1 mM
sodium fluoride, 1 mM sodium orthovanadate) supplemented
with protease inhibitors. Aliquots of cleared cell lysates containing
the same amount of protein (250 mg/sample) were incubated with
anti KDR antibodies, followed by incubation with Protein A
Sepharose. The immune complexes were washed with lysis
buffer, eluted by boiling in sample buffer, and analyzed by SDS-
PAGE. Densitometric analyses of the immunoblots were
performed using the National Institute of Health (NIH) Image J
program.
ELISA determination of VEGF levels
Cell supernatants were collected from HUVECs plated in 35-
mm Petri dishes, and VEGF measurements were performed using
commercially available ELISA kits (R&D Systems, Minneapolis,
MN, USA) following manufacturer’s instructions. VEGF levels
were expressed relative to total cell protein (pg/mg of total protein)
evaluated by BCA protein assay.
Preparation of nuclear extracts
HUVECs, plated in 100-mm diameter Petri dishes, were
washed with PBS and collected by scraping. The cells were then
lysed for 10 min at 4uC in buffer A (10 mM HEPES pH 8.0,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol (DTT),
0.05% Nonidet P-40, 1 mM sodium orthovanadate) supplement-
ed with protease inhibitors. After a 10 min centrifugation at
2,500 g at 4uC, the crude nuclei were washed with buffer A prior
to lysis in buffer C (20 mM HEPES pH 8.0, 1.5 mM MgCl2,
420 mM NaCl, 1.0 mM DTT, 0.2 mM EDTA, 1 mM sodium
orthovanadate, supplemented with protease inhibitors) for
30 min at 4uC. The nuclear extracts were clarified by
centrifugation, and loaded on a 10% SDS-PAGE. The immuno-
reactive bands were visualized by chemioluminescence after
overnight incubation with the anti HIF-1a antibody at a 1:500
dilution in 5% BSA in TBS-T.
Total RNA extraction for reverse transcription and
quantitative real time PCR
Total RNA was extracted using the RNeasyH Mini Kit and
accompanying QIAshredderTM (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. To avoid DNA
contamination of samples, a 15 min on column incubation was
carried out with DNase I (Qiagen). Reverse transcription was
performed using the SuperScript
TM
III First-Strand Synthesis
System for RT-PCR (Invitrogen), again following the manufac-
turer’s instructions. For quantitative analysis of gene expression we
used the ABI PrismH 7000 Sequence Detection System, SDS
software version 1.2.3 (Applied Biosystems, CA, USA). Target
sequences were amplified from 50 ng of cDNA. TaqManH Primer
and Probe assays used were: human VEGF-A (Hs99999070_m1),
KDR (Hs00176676_m1), eNOS (NOS3, Hs00167166_m1), HIF-
1A (Hs00153153_m1) and the endogenous control 18S
(Hs99999901_s1). For calculation of results, the 22DDCt method
was used allowing normalization to 18S and to the calibrator
which is set to a value of 1.
Transient transfection
HUVECs, plated in 35-mm Petri dishes, were transfected with
the expression vector pcDNA3ARNTdelta_b (DARNT) (kindly
provided by Dr. Tacchini, Department of Human Morphology
and Biomedical Sciences ‘Citta` Studi’, University of Milan,
Milano, Italy), coding for a dominant negative mutant form of
the HIF-1b ARNT subunit, and the void vector pcDNA3 using
TransITTM LT1 (Mirus, Bologna, Italy). Six hours after
transfection, the culture medium was replaced by fresh medium,
and the cells were exposed to L-NAME for the following 48 h.
Small interfering RNA (siRNA) transfection
Validated StealthTM RNAi duplexes against human eNOS (GC
content 48%) were provided from Invitrogen. As control RNA, we
utilized a StealthTM RNAi negative control duplex (Medium GC
Duplex, Invitrogen) with a 48% GC content, suitable for use as a
control with StealthTM RNAi duplexes containing 45-55% of GC.
All sets of RNAi molecules were transfected individually into
HUVECs at a 30 nM concentration using Lipofectamine 2000
according to the manufacturer’s instructions (Invitrogen). The
ability of the RNAi molecules to knockdown eNOS expression was
analyzed 48 h after transfection by western blot analysis.
Statistical procedures
All data were expressed as mean6 s.e.m. Statistical analysis was
carried out using one-way analysis of variance (ANOVA) followed
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by Bonferroni’s multiple comparison test or Student’s t-tests, where
applicable.
Reagents and antibodies
All tissue culture reagents were from Sigma Chemicals (St.
Louis, MO, USA). The following reagents were purchased as
indicated: human VEGF165 from Calbiochem (Darmstadt,
Germany); collagen type IV from BD Bioscience (Bedford, MA,
USA); L-NAME, ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-
1-one), DETA-NO (2,29 (hydroxynitrosohydrazono)bis-ethani-
mine) from Sigma Chemicals (St. Louis, MO, USA).
Antibodies used were: rabbit polyclonals anti caspase-3 (Cell
Signalling, Beverly, MA, USA), anti Bax and anti KRD (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and mouse
monoclonals anti Bcl-2 (Santa Cruz Biotechnology), anti eNOS,
anti HIF-1a (BD Transduction Laboratories, Franklin Lakes, NJ,
USA) and anti b-actin (Sigma Chemicals, St. Louis, MO, USA).
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